Etranacogene Dezaparvovec
Last Updated: 06/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B.
Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
Published: April 06, 2026
CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges.
Journal: Molecular therapy. Nucleic acids
Published: January 07, 2026
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.
Journal: The New England journal of medicine
Published: December 08, 2025
Deconstructing gene therapy in hemophilia for the clinician.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial.
Journal: Research and practice in thrombosis and haemostasis
Published: November 03, 2025
Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.
Journal: Journal of blood medicine
Published: October 22, 2025
Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies.
Journal: Blood reviews
Published: September 08, 2025
Overview of gene therapy for hemophilia: questions and answers to navigate the innovation.
Journal: Journal of thrombosis and haemostasis : JTH
Published: September 01, 2025
Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial.
Journal: Research and practice in thrombosis and haemostasis
Published: August 31, 2025
Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms.
Journal: Blood reviews
Published: August 17, 2025
Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.
Journal: Biomedicines
Published: July 06, 2025
Fitusiran (Qfitlia) for hemophilia A and B.
Journal: The Medical letter on drugs and therapeutics
Published: July 02, 2025
Last Updated: 06/24/2026